Abstract
Implementation of a quantitative molecular imaging method (iFRET), which determines receptor-ligand interactions, has led to the finding that patients with a low extent of PD-1/PD-L1 interaction in metastatic NSCLC, and malignant melanoma, display significantly worsened overall survival compared to those with a high level of interaction.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
B7-H1 Antigen / antagonists & inhibitors
-
B7-H1 Antigen / physiology
-
Biomarkers, Tumor / analysis*
-
Biomarkers, Tumor / isolation & purification
-
Carcinoma, Non-Small-Cell Lung / diagnosis
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Carcinoma, Non-Small-Cell Lung / mortality
-
Humans
-
Immune Checkpoint Inhibitors / therapeutic use
-
Immunohistochemistry / methods
-
Lung Neoplasms / diagnosis
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / genetics
-
Lung Neoplasms / mortality
-
Molecular Imaging / methods*
-
Neoplasms / diagnosis*
-
Neoplasms / drug therapy
-
Neoplasms / genetics
-
Neoplasms / mortality
-
Prognosis
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Programmed Cell Death 1 Receptor / physiology
-
Survival Analysis
-
Treatment Outcome
Substances
-
B7-H1 Antigen
-
Biomarkers, Tumor
-
CD274 protein, human
-
Immune Checkpoint Inhibitors
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor